bionomics-rgb-1024px.png
Bionomics’ Half-Year Report
23. Februar 2023 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
bionomics-rgb-1024px.png
Quarterly Activities and Cashflow Report
30. Januar 2023 18:23 ET | Bionomics Ltd
ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
bionomics-rgb-1024px.png
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
18. Dezember 2022 19:34 ET | Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
bionomics-rgb-1024px.png
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
15. Dezember 2022 18:35 ET | Bionomics Ltd
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
bionomics-rgb-1024px.png
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
02. Dezember 2022 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
21. November 2022 18:13 ET | Bionomics Ltd
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
bionomics-rgb-1024px.png
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
16. November 2022 18:36 ET | Bionomics Ltd
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
bionomics-rgb-1024px.png
Bionomics Limited to Participate in Upcoming November Investor Conferences
02. November 2022 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Quarterly Activities Report for September 2022
25. Oktober 2022 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
bionomics-rgb-1024px.png
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
18. Oktober 2022 06:00 ET | Bionomics Ltd
ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the...